Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
FAQs
Advertising
Report Store
UsernamePublicRestriction
Tags:

Forest Counting On Memantine, Benicar, To Bolster Growth Post-Celexa  

  • News

Executive Summary

Forest expects its Alzheimer's drug memantine to be approved for moderate to severe disease in the spring of 2004, Chief Operating Officer Kenneth Goodman said during a fiscal 2003 fourth quarter earnings call April 22

You may also be interested in...



Lexapro Switch Takes New Twist: Forest Launching Celexa Generic In 2005

Forest plans to launch a generic version of its antidepressant Celexa in early 2005

Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December

Forest is planning a slow roll-out of Namenda (memantine) after a faster-than-expected approval of the Alzheimer's agent

Lexapro Switch Takes New Twist: Forest Launching Celexa Generic In 2005

Forest plans to launch a generic version of its antidepressant Celexa in early 2005

Table

View full table

Related Content

Pink Sheet
Pink Sheet
Pink Sheet
Pink Sheet
Tags:
UsernamePublicRestriction

Register

LL1126230

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By